The Emory Clinic

The trials here

What the 21 trials at this site are about, from their registry records.

Conditions

• ALS (motor neurone disease)2 trials
• Chronic lymphocytic leukaemia2 trials
• Coronary artery disease2 trials
• Idiopathic pulmonary fibrosis2 trials
• Metastatic breast cancer2 trials
• Autism1 trial
• Bronchiectasis1 trial
• Cervical cancer1 trial
• Colorectal cancer1 trial
• Cystic fibrosis1 trial
• Depression1 trial
• Fabry disease1 trial
• and 9 more

Phase

• Phase 39 trials
• Phase 44 trials
• Phase 23 trials
• Phase 1/21 trial
• Phase 2/31 trial

Status

• Completed7 trials
• Recruiting6 trials
• Active, not recruiting5 trials
• Not yet recruiting2 trials
• Terminated1 trial

Lead sponsor

• Emory University4 trials
• Pfizer3 trials
• Amicus Therapeutics2 trials
• Biogen2 trials
• Boehringer Ingelheim2 trials
• and 6 more

Running trials

• Not yet recruiting

  Evaluating the Feasibility of Collecting User Interaction Data at the Emory Autism Center Using MapHabit Software

  NCT07859306· Emory University· Source

  Contact: Mikle South, PhD

• Recruiting

  A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

  NCT06876649· Phase 4· Eli Lilly and Company· Source

  Contact: Jonathon Cohen (principal investigator)

• Recruiting

  A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

  NCT06876662· Phase 4· Eli Lilly and Company· Source

  Contact: Jonathon Cohen (principal investigator)

• Recruiting

  Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

  NCT06952660· Phase 4· Pfizer· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

  NCT06274801· Phase 3· Gossamer Bio USA, Inc.· Source

  Contact: GB002 Inc.

• Recruiting

  Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

  NCT05943535· Phase 3· United Therapeutics· Source

  Contact: Mitzi Near

• Recruiting

  A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18

  NCT04808505· Phase 3· Amicus Therapeutics· Source

  Contact: For Site

• Recruiting

  Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

  NCT05850689· Phase 3· Intra-Cellular Therapies, Inc.· Source

• Active, not recruiting

  The Precision CAD Trial

  NCT04755413· Emory University· Source

• Active, not recruiting

  Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms

  NCT04856982· Phase 3· Biogen· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT04033445· Phase 2/3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

  NCT03485209· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic lymphocytic leukaemia2 recruiting
• Autism1 recruiting
• Cervical cancer1 recruiting
• Depression1 recruiting
• High blood pressure1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Pompe disease1 recruiting
• Pulmonary arterial hypertension1 recruiting

Closed trials

• Completed

  Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis

  NCT05743946· Phase 4· Emory University· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

  NCT04539938· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Terminated

  A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation

  NCT04494256· Phase 1/2· Biogen· Source

• Completed

  Mental Stress and Myocardial Ischemia After MI: Sex Differences, Mechanisms and Prognosis

  NCT04123197· Emory University· Source

• Completed

  Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

  NCT04049760· Phase 3· Amicus Therapeutics· Source

• Completed

  A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

  NCT02684006· Phase 3· Pfizer· Source

• Completed

  A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

  NCT01740427· Phase 3· Pfizer· Source